Hypofractionated Radiation Therapy for Carcinoma, Mammary Ductal
This study is evaluating whether a type of radiation therapy may help prevent cancer from returning in patients who have had a mastectomy.
See full descriptionAbout the trial for Carcinoma, Mammary Ductal
Treatment Groups
This trial involves 2 different treatments. Hypofractionated Radiation Therapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Hypofractionated Radiation Therapy will improve 1 primary outcome and 10 secondary outcomes in patients with Carcinoma, Mammary Ductal. Measurement will happen over the course of At to 24 months.
Patient Q & A Section
What are the signs of carcinoma, mammary ductal?
Patients with carcinoma of the breast should receive mammography, clinical examination, and breast ultrasonography regularly. They should also be counselled concerning [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) at each stage of the disease. They should be made aware that at any stage mammography will detect 85% of cancers and that breast biopsy is unnecessary. Breast self-examination in young women should be encouraged, and regular examination to exclude calcification by X-ray is essential. The use of prophylactic oophorectomy in post-menopausal women with breast cancer has been studied with contradictory results. The majority of patients prefer the operation.
What causes carcinoma, mammary ductal?
It is possible that cancers develop from pre-cancerous lesions involving the mammary ducts. Carcinoma and carcinoma, ductal, are not completely separate entities of neoplasia of the breast. It is now believed that they may represent a single lesion with carcinoma and more recently a distinct spectrum of tumours with different disease behaviour.
How many people get carcinoma, mammary ductal a year in the United States?
About 20 million women in the United States have at least one major depressive episode each year. Women with carcinoma, mammary ductal are more than twice as likely to have a major depressive episode compared with women without carcinoma, mammary ductal.
What are common treatments for carcinoma, mammary ductal?
Most treatments for SCTs include the same procedures used in the treatment of most breast cancers. Most treatments involve surgery, chemotherapy or radiation. Very rarely a mastectomy is the indicated treatment.
Can carcinoma, mammary ductal be cured?
Recent findings, no cases of carcinoma were cured after operation. Survival of all patients was poor, because all patients had other major medical comorbidities, including cancer, and some had distant metastasis without local disease.
What is carcinoma, mammary ductal?
Carcinoma, mammary ductal is a rare type of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) that is predominantly found in postmenopausal women who have a history of breast disease. Cancers associated with carcinoma, mammary ductal include lobular carcinoma in situ, atypical ductal hyperplasia, papillary carcinoma, and juvenile ductal carcinoma. In the United States, carcinoma, mammary ductal is one of the most common forms of breast cancer among adults.
What is hypofractionated radiation therapy?
The use of hypofractionated radiation therapy delivers radiation with fewer doses but with shorter treatment times and achieves similar long-term effectiveness to more concentrated approaches. A hypofractionated approach may be appropriate for treating inoperable carcinomas of the breast because of short treatment duration and few treatment doses. This approach may reduce the risk of developing acute toxicity and treatment breaks in patients who would not tolerate protracted courses of radiation.
How serious can carcinoma, mammary ductal be?
Carcinoma, mammary ductal is, by far, most deadly malignant neoplasm. These data are in agreement with the hypothesis that the prognosis is influenced by factors independent of tumor size or spread, including gender, age, stage, and underlying systemic disease that may be associated with increased risk for future disease recurrence.
Have there been any new discoveries for treating carcinoma, mammary ductal?
The current treatments for luminal cancers are based on the assumption that they are all of the same type of tumor. We summarize the potential therapies for treating all of the luminal types.
Has hypofractionated radiation therapy proven to be more effective than a placebo?
In this small pilot study, there was no improvement in local control or loco-regional control with hypofractionated radiation compared with the placebo. Hypofractionated RT was found to be safe and tolerable. Although the study is limited by its small sample size, the results do indicate that more work is needed before a larger trial can be considered.
What is the survival rate for carcinoma, mammary ductal?
If the disease has metastasised only to the lungs then prognosis is dismal (median survival 9.3 months, 95% confidence interval 4.9-14.5). If the disease has metastasised to other sites then overall survival is 2–3 years (median 12 months, 95% confidence interval 3.4-24.7). Survival is not very good for patients who present with systemic disease (median 6.6 months, 95% confidence interval 4.9-8.5).